Retifanlimab prolongs overall survival in advanced squamous cell anal cancer
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study
Study findings support a growing shift towards “personalised de-escalation” treatment strategies in anal and rectal cancer care
Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers
Addition of immunotherapy to chemotherapy improves progression-free survival in anal canal
The PODIUM-303 study shows practice-changing results for patients with unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal